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130 D e g r a d a t i o n of B i o a c t i v e Substances: P h y s i o l o g y a n d P a t h o p h y s i o l o g y 
I. INTRODUCTION 
Atrial natriuretic factor (ANF) is the first well-defined natriuretic hormone. The best 
characterized pharmacological and partly physiological actions of A N F are natriuresis, diu-
resis, and smooth muscle relaxation (for review, see References 1 to 12). Recently, evidence 
has been provided that A N F might be involved in various other biological actions apart from 
its role in volume homeostasis such as immune or reproductive functions. 1 3 - 1 7 
A N F is synthesized in the human heart as a 151 amino acid preprohormone and stored as 
a 126 amino acid prohormone. Upon appropriate Stimulation, such as atrial Stretch, the 
prohormone is cleaved into an N-terminal and C-terminal fragment. The latter has been 
identified as the circulating bioactive A N F 99-126. 1 8 , 1 9 A body of investigations has concen-
trated on the mechanisms of A N F release and on its biological actions (for review, see 
References 1 to 14). Thus far, there is much less information on the processing of A N F 
prohormone as well as on the clearance of bioactive A N F . However, these seem to be topics 
of considerable interest, since plasma levels and biological activity of A N F are significantly 
influenced by these processes. This review article will concentrate on the mechanisms of A N F 
prohormone processing and of degradation and clearance of bioactive A N F , including pa-
thophysiological aspects and possible therapeutic implications. The still poorly understood 
metabolism of A N F in the central nervous System will not be addressed in this chapter. 
II. PROCESSING OF ATRIAL NATRIURETIC PROHORMONE 
A. THE HEART 
It is well established that the heart atria represent the major site of synthesis for A N F (for 
review, see References 20 and 21). Atrial muscle cells possess well-developed structures 
necessary for synthesizing, packaging, and storing this peptide. Initially, a common precursor 
termed prepro-ANF, which comprises between 149 and 153 amino acids depending on the 
species (151 amino acids in human), is being synthesized (see Figure 1). This prepro A N F 
molecule contains a signal peptide sequence at its amino terminus which seems to provide the 
signal for the co-translational transport of the peptide across the endoplasmatic reticulum. 
Düring this transport, the signal sequence is removed and the resulting 126-amino acid peptide 
is stored in secretory granules. In contrast to other prohormone forms of secreted proteins 
(e.g., proinsulin, prepromelanocortin, and proenkephalin) which are being cleaved to the 
mature form during vesicular packaging,22 2 4 the A N F prohormone is stored in the atrial 
granules as the unprocessed prohormone.25 The only 28-amino acid comprising carboxytermi-
nus ANF(99-126) (see Figure 2) represents the biologically active hormone and is released 
together with the N-terminal ANF(l-98) into the circulation. 1 9 , 2 6 - 3 0 The site and exact mecha-
nism of this proteolytic conversion of ANF( 1-126) to ANF(99-126) is not yet known. Two 
possible mechanisms have to be considered. First, the cleavage occurs during secretional 
processing; this concept is supported by i n v i t r o experiments showing that ANF(99-126) is 
released from isolated perfused hearts27-31 and by the fact that plasma is not capable of 
performing the cleavage.32 Secondly, data showing that isolated cultured myocytes release the 
intact pro-ANF provide evidence that the cleavage does occur extracellular of myocytes.33-34 
However, cleavage does not seem to take place in the circulation, because the release of 
ANF(99-126) from the isolated perfused rat heart seems not to be dependent on serum related 
enzymes.32 In this regard, one must be aware of the fact that processing of ANF(1-126) from 
isolated cultured cells must not necessarily correspond to the i n v i v o conditions. Taken 
together, the cleavage of pro-ANF may take place during secretion, as well as shortly after 
secretion from the myocytes. 3 5 - 3 8 
In this context, the knowledge of the enzyme responsible for selectively cleaving the 
prohormone and, moreover, of its cellular or subcellular localization would be helpful to 
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FIGURE l. Schematic Illustration of various ANF forms: synthesized 
prepro-ANF is stored as ANF( 1-126), the prohormone. Upon release 
and cleavage, ANF(99-126), the circulating C-terminal fragment, exerts 
biological activities. 
Amino acid sequence of human ANF(99-126) 
Arg 113 Gly 
A / 112 114 \ , 
Asp Ala 
111 115 \ 
/ 110 116 \ 
Arg 109 H 7 S e r 
J . 1 « 1 1 8 J . Gly Gly 
\ 107 119/ 
Gly .o^Gly 
* 106 120/ 
P h e . i o s 121 / G , y 
Cys-3-S-Cys 
Ser Asn 
Ser Leu-Arg Arg Ser 104 122 "Ser-Phe-Arg-Tyr 
99 100 101 102 103 123 124 125 126 
FIGURE 2. Amino acid sequence of the biologically active ANF(99-126). 
elucidate this question. Recently, a serylprotease has been isolated from atrial tissue which 
selectively cleaves the Arg 98-Ser 99 bond of pro-ANF, resulting in ANF(99-126) and 
ANF(l-98) . 3 9 , 4 0 The exact location of this peptide is still controversial. Several possibilities are 
being proposed: 
1. Location of a serine protease with A N F (99-126) Substrate specificity was described in 
the atrial granules containing ANF(1-126). 4 0 This finding can hardly be reconciled with 
the absence of ANF(99-126) in these granules.25 
2. The microsomal fraction,39 rather than the granule fraction of atrial cells, containing this 
enzyme activity would be in line with our understanding that pro-ANF is most likely 
cleaved during exocytotic secretion from its storage granules. Myocytes, but also 
adjacent atrial mesenchymal cells, may possess such an extragranularly located en-
zyme. 3 6 
3. Aiternatively, this enzyme might be situated extracellularly;36 however, this hypothesis 
has not been backed up by experimental fmdings thus far. 
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B. PROCESSING IN VARIOUS OTHER ORGANS 
Over the years, evidence has accumulated that the heart is not the only peripheral site of 
A N F synthesis.4011 Lung, 4 1 adrenals,42 intestine,17 various lymphoid organs,1 5 , 4 3 and female re-
productive organs1 6 , 4 4 have been reported to contain A N F prohormone. So far, only the lung 
and the adrenals have been shown to be able to secrete ANF(99-126). 4 5 4 6 This suggests that 
maturation processes occur in these organs. In cultured chromaffin cells, both the prohormone 
as well as the mature form of A N F are co-secreted45 whereas the lung releases only ANF(99-
126).46 
No information about the exact mechanism of these maturation processes is available, 
however, a contribution of extraatrial A N F to the circulating A N F pool is being discussed. 4 1 4 6 
HL CLEARANCE OF BIOACTIVE ANF 
A. ORGAN CLEARANCE 
Plasma levels of bioactive A N F are determined by both release and clearance. While there 
is a rieh body of information about A N F release, the number of studies on the clearance of this 
peptide is rather limited. 4 7" 6 3 The ability of various organs to clear A N F from the circulation 
can be described by the extraction ratio or by the organ clearance. The extraction ratio is 
calculated as arterial minus venous blood concentration over arterial blood concentration (%). 
Multiplication of the extraction ratio with the organ plasma flow results in the organ clearance 
(liter/minute). Several aspects and possible pitfalls have to be taken into consideration regard-
ing studies on A N F metabolism: since the studies necessarily apply venous and even arterial 
catheterization, for ethical reasons, many investigations have been done in patients with 
hypertension or congestive heart failure rather than in healthy subjects. Some of the studies 
did not determine organ plasma flow, thus restricting their results to extraction ratios. Extrac-
tion ratios as well as organ clearance have been determined both under basal conditions and 
following intravenous A N F administration. For clearance determinations of pharmacologi-
cally active A N F doses, specific attention should be paid to the rate of infusion in order to 
achieve steady-state conditions. Problems may arise by inappropriate intervals of plasma 
sampling. Furthermore, administration of A N F may decrease blood pressure,56 affect cardiac 
Output and organ blood flow, and increase glomerular filtration rate; this might result in under-
or overestimation of A N F clearance as compared to physiological conditions. 
Furthermore, some studies are based on the assumption that there is no pulmonary extrac-
tion of ANF. However, there is now evidence, obtained by pulmonary wedge or pulmonary 
venous sampling, 4 7 , 4 8 that the lung is an important site for A N F extraction. 
With these reservations in mind, it seems that there is no major organ speeificity for A N F 
extraction. Lung, liver, kidney, intestine, and lower limb show similar extraction ratios within 
the respective studies. Values reported, however, differ considerably between various studies 
(Table i) 47-51,53.54,56.58-61.63 Extraction ratios were reported to be 0 to 33% for lung, 22 to 75% 
for liver and intestine, 23 to 67% for kidney, and 15 to 61 % for the lower limb. Taken together, 
it seems that there is a general arterio-venous organ extraction ratio for A N F of about 35%. 
Since there are marked differences of organ blood flow, obviously total A N F clearance 
differs considerably between various organs. Few investigations have determined organ blood 
flow together with A N F extraction under physiological or steady-state conditions. 4 7 , 4 9 , 5 1 , 5 6 
About 50% of the total body clearance of A N F seems to be furnished by the lung. 4 7 The 
renal 4 7 , 4 9 , 5 1 (around 15%) and splanchnic-hepatic47 ,49 ,56 (about 20%) vascular beds also contrib-
ute significantly to A N F clearance. 
Several mechanisms could aecount for the above-mentioned organ clearance of A N F : 
reeeptor-mediated uptake, enzymatic degradation, or organ-speeifie exeretion (urine or bile). 
However, there are only a few reports of concentrations of A N F in bile 4 7 or urine. 5 7 , 6 2 The 
following sections in this chapter will cover enzymatic degradation of A N F , as well as A N F 
clearance reeeptors. 
T A B L E 1 
Clearance of ANF by Various Organs 
ANF arterio-venous extraction ratio (%) 
Author/ Arterial Liver/ Lower 
year Species Healthy (n) sampling site Kidney intestine Lung limb Ref. 
Crozier, 1986 Man No 4—8 Pulmonary/ 50 45 <10 50 58 
aortic 
Henriksen, 1986 Man Yes 8—14 Femoral 54 28 — 40 54 
Schütten, 1987 Man ? 8—14 Pulmonary/ 54 28 0 40 53 
femoral 
Gines, 1988 Man 7 11 Pulmonary — 71 — 61 63 
Vierhapper, 1988 Man Yes 6 Femoral — 75 — — 56 
Woods, 1988 Dog Yes 5 Aortic 55 — — — 51 
Bates, 1989 Dog Yes 14 Pulmonary — — 32 — 48 
Hollister, 1989 Man No 8—39 Pulmonary/ 35 30 24 38 47 
aortic 
Dog Yes 4—7 Pulmonary/ 42 36 19 — 
aortic 
Krieter, 1989a Rat Yes 4—7 Femoral 55—61 22-44 — 43—54 49 
Kurosawa, 1989 Man No 6—56 Pulmonary/ 23 24 12 15 59 
femoral/coeliac/ 
renal 
Masuda, 1989 Dog Yes 6 Pulmonary/ 34 28 33 — 50 
renal/ 
hepatic 
Sudhir, 1989 Man Yes 6 Brachial 67 — — — 61 
Henriksen, 1990 Man Yes 6 Femoral — 53 — — 60 
a Data obtained during ANF infusion. 
N o t e : Arteriovenous extraction ratios are calculated as (arterial minus venous) over arterial ANF plasma concentrations and given in percent (%). Sites of sampling 
for arterial blood are shown in the shown in the table; ideally the arterial plasma concentrations should be determined in the respective organ-supplying 
arteries. —: not determined. 
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1. Enzymatic Degradation 
Since the kidney is a major target organ for A N F , interest has focused on this organ, not 
only as a site for receptor mediated clearance of this peptide (see Section III.A.2), but also as 
a tissue which may be able to enzymatically degrade circulating ANF(99-126). 
Peptidase degradation of A N F is considered to play an important role among possible 
clearance mechanisms64-65 (see also Chapter 4). The brush border of the renal proximal tubule 
is known to be very rieh in peptidases. These enzymes are membrane bound and their active 
sites face the lumen of the tubule.66 Incubating ANF(99-126) with these kidney microvilli 
results in a major degradation produet cleaved between cysteine and Phenylalanine (Cys 105-
Phe 106).6 4-6 5-6 7 - 6 9 Since the intact ring strueture of ANF(99-126) is essential for its biological 
activity, 7 0 , 7 1 A N F is effectively inactivated by this cleavage process. 
The properties of the A N F degrading activity have been investigated by several groups. 
The responsible substance is a glycoprotein 6 4 , 6 7 , 6 9 with a molecular weight of approximately 
94 kDa, sensitive to metalloendoprotease inhibitors such as phosphoramidon and thiorphan. 
In view of these findings, the major proteolytic enzyme responsible for the A N F cleavage 
seems to be the endoprotease EC 3.4.24.1 1.6 3 , 6 7 , 6 9 EC 3.4.24.11 has been reported also to 
possess enkephalin degrading activity. 7 2 However, there may be various forms of EC 
3.4.24.11 differing in cleavage site speeificity and tissue distribution.6 7 , 7 3 7 7 Thus, one may 
speculate that the kidney possesses a specific type of endoprotease EC 3.4.24.11. 
Apart from the major cleavage site within the loop strueture, secondary attack by amin-
opeptidases has been hypothesized.64 These enzymes are not initially responsible for degra-
dation because specific inhibitors like Captopril or amastatin have no significant effect.64 After 
the major cleavage process at the Cys-Phe bond of the ring strueture, more complex degra-
dation processes seem to follow, producing smaller A N F fragments.68The major sites of renal 
A N F degradation by the endopeptidase seem to be the proximal tubule and the glomerulus.78 
Prompted by these observations, efforts have been made to develop A N F analogues which 
are resistant to this enzyme, as well as specific enzyme inhibitors which could be therapeu-
tically employed (see Section III.C). 
Recent reports indicate A N F degrading activity by the vasculature79 and the adrenal 
capsule.7 3No information is available about the enzymatic degradation activity of other organs 
reported to contribute to A N F clearance (see Section III.A). 
2. Clearance Receptors 
Specific binding sites for A N F have been identified on various cells such as endothelial 
cells, vascular smooth muscle cells, inner medullary collecting duet cells, and in various 
organs such as lung, kidney, adrenal gland, liver, and intestine.8 0 - 8 2 Several observations 
demonstrate that there are at least two different types of A N F receptors with different 
molecular size and different biological properties.83-88 The development of truncated A N F 
analogues which selectively bind to one receptor type such as des[(18-22)]-rANF(4-23)-
N H 2 , 8 9 , 9 0 recently has allowed for better quantitative discrimination of both receptors. 
The current coneept of both receptors is as follows: the 130-kDa receptor exhibits a higher 
affinity for circulating biologically active A N F , is coupled to cyclic guanylate cyclase, and 
mediates the biological effects. Thus, it has been called B- (biological) or R,-receptor. The 
other receptor type shows a molecular weight of 65 kDa, exhibits a lower affinity to biologi-
cally active A N F , and binds truncated A N F analogues; it has thus been called C- (clearance) 
or R 2-receptor. 9 1 - 9 4 C-receptors might mediate suppression of adenylate cyclase activity by 
ANF. 9 5 , 9 6Interestingly, it has been shown that the C-receptor may regulate the biologic activity 
of endogenously released A N F , 9 4 and there is evidence that this receptor type indeed has a 
clearance funetion.91 
In anesthetized rats, administration of an A N F analogue selectively binding to C-receptors 
induced marked dose-dependent increases of ANF(99-126) plasma concentration and de-
creases of its volume of distribution and metabolic clearance rate. Furthermore, there is 
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evidence that a major part of A N F mertabolism is due to an internalization following the 
binding of circulating A N F to the C-receptor and subsequent intralysomal hydrolysis.91 The 
regulation of the C-receptor is poorly understood as yet. There is evidence that maneuvers 
decreasing intravascular volume decrease A N F plasma levels and, in turn, increase total A N F 
receptor density.97 9 9 Surprisingly, this increase of A N F receptor density is coupled to a 
reduced biological response to ANF. The Observation that C-receptors, but not B-receptors, 
are augmented following dehydration100 could explain this seeming contradiction and indi-
cates that regulation of C-receptor density might be involved in volume homeostasis. There 
are few data on the quantitative relationship between B- and C-receptors in various tissues. In 
the kidney, in particular on glomeruli, the majority of A N F receptors seems to be of the 
clearance type. 1 0 0 1 0 1 The same has been observed on cultured bovine aorta endothelial cells, 8 3 
on adrenal zona glomerulosa cells, 1 0 1 and on lung membranes.88 
These recent observations are compatible with the concept of a functional importance for 
the C-receptors, which are distinctly different from the B-receptors, in the clearance of A N F 
— a rather unique mechanism in the metabolism of peptides. 
B. PATHOPHYSIOLOGY 
Elevated plasma concentrations of A N F have been found in various pathophysiological 
states, such as congestive heart failure, renal failure, and in some patients with liver disease 
(see References 102 to 105). An increased release of A N F has been suggested in these 
diseases. 6 3 1 0 6 1 0 9 However, elevated plasma concentrations might also be caused by decreased 
clearance. To date, little is known about clearance in pathophysiological states. Recently, it 
has been reported that the fractional extraction of various organs is unchanged in patients with 
liver cirrhosis.54In an experimental model, it has been shown that the renal clearance of A N F 
varies considerably, depending upon glomerular filtration rate;51 thus, augmented A N F 
plasma concentrations in renal diseases might be partly due to reduced A N F elimination. The 
Proportion of B- and C-receptors for A N F in aorta, adrenal, and kidney seems unchanged in 
experimental congestive heart failure.101 In an experimental model of cirrhosis, C-receptor 
density on glomeruli was increased, whereas B-receptors tended to be decreased;1,0 however, 
these animals were not investigated for A N F clearance. Clearly, there is a need for further 
investigations on whether and how metabolic clearance and degradation of A N F is affected 
by pathophysiological states. 
C. THERAPEUTIC IMPLICATIONS 
Beneficial effects of A N F application have been reported in congestive heart failure, 
hypertension, renal failure, chronic obstructive lung disease, and liver disease. 1 1 1 - 1 1 8 Aug-
mented circulating levels of A N F may be achieved by exogenous administration of A N F . Due 
to the peptide character of the substance, A N F can be administered only intravenously. The 
rapid metabolic clearance" 9 - 1 2 1 makes repeated bolus injections or continuous infusions 
necessary. Alternatively, circulating A N F concentrations might be elevated by blocking its 
clearance. This might be achieved by administering truncated analogues, binding to clearance 
receptors only and, thus, augmenting the concentration of A N F reaching the B-recep-
t o r s 91.94.122 
Furthermore, inhibitors of the A N F degrading peptidase might show the same results. 
Indeed, several investigations employing endopeptidase EC 3.4.24.11 inhibitors 1 2 2 - 1 3 2 showed 
that the circulating A N F immunoreactivity was elevated and this was accompanied by an 
augmented biological activity, such as increased urinary volume and sodium excretion. 
Interestingly, these chemicals seem to be especially useful in pathophysiological conditions. 
They have been shown to enhance the biological activities (natriuretic and depressor re-
sponses) of A N F in experimental models of hypertension 1 2 4 1 3 0 - 1 3 2 and volume expansion.128 
Further investigations will evaluate the potential of this rather elegant therapeutic approach. 
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IV. SUMMARY 
Atrial natriuretic factor, the first well-defined natriuretic hormone is synthesized in the 
human heart as 151 amino acid (AA) preprohormone and stored as 126 A A prohormone in 
atrial granules. Upon appropriate Stimulation, the prohormone is cleaved into a 98 A A N -
terminal fragment and a 28 A A C-terminal fragment, the biological active ANF(99-126), both 
circulating in plasma. The cleavage occurs most likely either during or shortly after the release 
from the myocyte granules. The respective enzyme, a serylprotease, is discussed as being 
bound to plasma membranes of myocytes or of atrial mesenchymal cells. There is increasing 
evidence for A N F synthesis and processing in peripheral organs other than the heart. 
Circulating ANF(99-126) is cleared by various organs such as lung, liver, intestine, kidney, 
and upper and lower limbs. Reported arterio-venous extraction ratios vary greatly, but do not 
differ much between organs, the average extraction ratio being bout 35%. Due to marked 
differences of organ blood flow, the contribution of various organs to total body A N F 
clearance differs considerably. 
Major mechanisms for A N F clearance are uptake by clearance receptors and degradation 
by an endoprotease EC 3.4.24.11. Clearance receptors, distinctly different from the receptors 
mediating the biological actions of A N F , have been demonstrated in various organs. Charac-
terization of the A N F degrading enzyme activity has been performed in kidney tissue. 
Whether and how pathophysiological states affect A N F clearance is still poorly understood. 
Inhibition of clearance by A N F analogues binding to clearance receptors and by inhibitors of 
degrading peptidase can increase the biological action of circulating A N F . This may prove to 
be a therapeutic approach in diseases with smooth muscle contraction or volume overload. 
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